APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed

DGAP-News: APONTIS PHARMA AG / Key word(s): Half Year Report/Half Year Results
APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
11.08.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
 

• Revenue from Single Pills +26.0% to EUR 17.7 million remains a key growth driver
• Single Pill share of revenue increases to 62.9% (H1 2021: 58.5%)
• Total sales rise by 17.1% to EUR 28.1 million
• EBITDA increases by EUR 3.9 million to EUR 3.2 million
• EBITDA margin improves to 11.6% (H1 2021: -2.9%)
• Market launch of two new Single Pills in the first half of the year
• Sales and earnings forecast for 2022 confirmed

Monheim am Rhein, 11 August 2022. APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, has continued its growth strategy with sustained sales and earnings growth in the first half of 2022. In this context, the market launch of two new Single Pills was supported by the two full publications of the START Study in two peer-reviewed journals, the results of which underscore the economic as well as the clinical superiority of a Single Pill therapy compared to loose combination therapy in cardiovascular diseases and thus support the current recommendations of medical societies.

APONTIS PHARMA grew by posting a 17.1% increase in sales to EUR 28.1 million in the first half of 2022, with Single Pill revenues continuing to be the main driver of growth, with an increase of 26.0% to EUR 17.7 million. The share of Single Pills in total sales increased to 62.9% (H1 2021: 58.5%). Sales from co-marketing, co-promotion and distribution rose by 2.6% to EUR 9.1 million.

On the purchasing side, the higher procurement costs for the product Ulunar® were particularly noticeable. In contrast, the sale of three gynecology products from the so-called legacy business resulted in a positive earnings contribution of EUR 0.6 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) increased to EUR 3.2 million in the first half of 2022 (H1 2021: before IPO costs of EUR 2.8 million) due to strong growth in sales despite higher expenses for accelerating commercialization activities.

Cash flow from operating activities improved to EUR 5.0 million (H1 2021 EUR 2.7 million) due to the positive result and reduced working capital. With an equity ratio of 73.1% and cash and cash equivalents of EUR 32.2 million, APONTIS PHARMA has a solid asset and financial position for the realization of its future growth targets.

For financial year 2022, the Management Board continues to expect sales of EUR 55.3 million and EBITDA of EUR 5.5 million.

Unaudited Group Figures

Note: The figures for the first half of 2022 are unaudited. Rounding differences are possible.

Karlheinz Gast, CEO of APONTIS PHARMA AG: “We achieved a lot in the first half of 2022 and continued to consistently implement APONTIS PHARMA AG’s growth strategy. It is particularly pleasing that with the launches of Tonotec Lipid and AmloAtor already in May and the launch of RosuASS in July 2022 (only a few days after the end of the reporting period), we lived up to our announcements of three Single Pill launches in the full year 2022. These three Single Pills alone have a combined mid-term sales potential of EUR 10.7 million. The excellent operational development is contributing to realizing our vision: To establish the Single Pill as the gold standard. For a better life. Together. Every day. By the end of 2023, we want to expand our Single Pill portfolio from ten to 13 products. We currently have 30 projects in our medium-term development pipeline. Shortly after the end of the reporting period, we also agreed a further development partnership with Midas Pharma in July for the market launch of a Single Pill with pan-European intellectual property rights, which we expect to be launched in 2026/2027. Thus, we see ourselves fully on track with regard to our medium-term targets of at least 20 Single Pills by 2026.”

APONTIS PHARMA AG’s 2022 half-year report is available on the company’s website at ir.apontis-pharma.de.

Webcast/Phone Conference:

CEO Karlheinz Gast, CPO Thomas Milz and CFO Thomas Zimmermann will explain the results of the first half of 2022 in a webcast presentation today, 11 August 2022, 9:00 CEST. The presentation will be held in English.

Please register in time to participate at:

APONTIS PHARMA 2022 Half Year Report – Webcast/Phone Conference.

The accompanying presentation will also be available on the company’s website prior to the start.

Condensed Consolidated Statement of Income (unaudited)

Note: The figures for the first half of 2022 are unaudited. Rounding differences are possible.

Condensed Consolidated Statement of Financial Position (unaudited)

Note: The figures as of 30 June 2022, are unaudited. Rounding differences are possible.

Condensed Statement of Cash Flows (unaudited)

Note: The figures for the first half of 2022 are unaudited. Rounding differences are possible.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact
CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330

11.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de